ML-RET-5 / RM-MET
Retatrutide
An investigational triple-receptor agonist peptide. Human phase 2 data has been published. It is not a component of any FDA-approved drug.
The listed price is the four-week total for this weekly option. Eight- and twelve-week totals are calculated as exact two- and three-month multiples.
Evidence position
Human evidenceEvidence grade B: Human evidence
Grade B. Human interventional evidence exists; no approved comparator. FDA has stated retatrutide cannot be used in compounding under federal law.
Full reference entryDocuments
- Lot
- Assigned at fulfilment
- Origin
- Confirmed with the lot record
- Analytical record
- Lot-linked documentation is confirmed with the written response.
Monthly supply options
- ○ML-RET-2.52.5 mg weekly4-week priceVerifyingSupplyVerifying
- ●ML-RET-55 mg weekly4-week priceVerifyingSupplyVerifying
- ○ML-RET-7.57.5 mg weekly4-week priceVerifyingSupplyVerifying
- ○ML-RET-1010 mg weekly4-week priceVerifyingSupplyVerifying
- ○ML-RET-12.512.5 mg weekly4-week priceVerifyingSupplyVerifying
- ○ML-RET-1515 mg weekly4-week priceVerifyingSupplyVerifying